Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol for Mucosal Healing in Small Bowel Crohn's Disease
NCT01053559Phase 4Completed
- Sponsor
- Shafran Gastroenterology Center
- Start
- Jan 2010
- Primary completion
- Sep 2013
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 4 trial of certolizumab pegol in Crohn's disease, sponsored by Shafran Gastroenterology Center. Started Jan 2010; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01053559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01053559.